AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clayette, P.
Right arrow Articles by Dormont, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clayette, P.
Right arrow Articles by Dormont, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 405-407, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Effects of MS-8209, an Amphotericin B Derivative, on Tumor Necrosis Factor Alpha Synthesis and Human Immunodeficiency Virus Replication in Macrophages

Pascal Clayette,1,2,* Marc Martin,1 Vincent Beringue,1 Nathalie Dereuddre-Bosquet,1,2 Karim T. Adjou,1,3 Michel Seman,4 and Dominique Dormont1

CEA, Service de Neurovirologie, DSV/DRM, CRSSA, IPSC, Fontenay aux Roses,1 SPI-BIO, Massy,2 Laboratoire d'Immunodifférenciation, Université Denis Diderot, Paris,4 and Laboratoires Mayoly-Spindler, Chatou,3 France

Received 5 May 1999/Returned for modification 10 August 1999/Accepted 18 October 1999

Amphotericin B derivatives, such as MS-8209, have been evaluated as a therapeutic approach to human immunodeficiency virus (HIV) infection. We show that MS-8209, like amphotericin B, increases tumor necrosis factor alpha (TNF-alpha ) mRNA expression and TNF-alpha production and consequently HIV replication in human macrophages. These effects confirm the pharmacological risk associated with the administration of amphotericin B or its derivatives to HIV-infected patients.

* Corresponding author. Mailing address: Service de Neurovirologie, CEA/DSV/DRM, 60-68, avenue de la Division Leclerc, B.P. 6, 92265, Fontenay aux Roses Cedex, France. Phone: 33 (0)1 46 54 87 69. Fax: 33 (0)1 46 54 77 26. E-mail: clayette{at}dsvidf.cea.fr.

Antimicrobial Agents and Chemotherapy, February 2000, p. 405-407, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.